NCT01464099View on ClinicalTrials.gov

Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin aspart

An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion

DRUG

insulin aspart

An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion

Trial Locations (1)

91911

Novo Nordisk Investigational Site, Chula Vista

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY